ホジキンリンパ腫(Hodgkin Lymphoma)の治療薬パイプライン動向（2015年上半期版）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 8
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Hodgkin Lymphoma Overview 11
Therapeutics Development 12
Pipeline Products for Hodgkin Lymphoma – Overview 12
Pipeline Products for Hodgkin Lymphoma – Comparative Analysis 13
Hodgkin Lymphoma – Therapeutics under Development by Companies 14
Hodgkin Lymphoma – Therapeutics under Investigation by Universities/Institutes 17
Hodgkin Lymphoma – Pipeline Products Glance 18
Late Stage Products 18
Clinical Stage Products 19
Early Stage Products 20
Hodgkin Lymphoma – Products under Development by Companies 21
Hodgkin Lymphoma – Products under Investigation by Universities/Institutes 24
Hodgkin Lymphoma – Companies Involved in Therapeutics Development 25
4SC AG 25
Acetylon Pharmaceuticals, Inc. 26
Actinium Pharmaceuticals, Inc. 27
Affimed Therapeutics AG 28
Aptose Biosciences Inc. 29
AVEO Pharmaceuticals, Inc. 30
Bristol-Myers Squibb Company 31
Constellation Pharmaceuticals, Inc. 32
Dynavax Technologies Corporation 33
Gamida Cell Ltd. 34
Incyte Corporation 35
Johnson & Johnson 36
MABLife S.A.S 37
Merck & Co., Inc. 38
Novartis AG 39
Ono Pharmaceutical Co., Ltd. 40
Pharmacyclics, Inc. 41
Philogen S.p.A. 42
Seattle Genetics, Inc. 43
Sigma-Tau S.p.A. 44
Spectrum Pharmaceuticals, Inc. 45
Stemline Therapeutics, Inc. 46
Syndax Pharmaceuticals, Inc. 47
Takeda Oncology 48
Tekmira Pharmaceuticals Corp. 49
TG Therapeutics, Inc. 50
Hodgkin Lymphoma – Therapeutics Assessment 51
Assessment by Monotherapy Products 51
Assessment by Target 52
Assessment by Mechanism of Action 55
Assessment by Route of Administration 58
Assessment by Molecule Type 60
Drug Profiles 62
abexinostat hydrochloride – Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
AFM-13 – Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
APTO-253 – Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
BMS-986016 – Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
brentuximab vedotin – Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Cell Therapy 2 for Oncology and Infectious Disease – Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Cell Therapy to Target CD30 for Hodgkin and Non-Hodgkin Lymphomas – Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Cell Therapy to Target CD30 for Relapsed and Refractory Lymphomas – Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Cell Therapy to Target LMP, BARF-1 and EBNA1 for EBV Associated Cancers and Infection – Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
Cell Therapy to Target LMP-1 and LMP-2 for Oncology – Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Cell Therapy to Target LMP-1 and LMP-2 for Oncology and Infectious Diseases – Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
Cell Therapy to Target NY-ESO-1, MAGEA4, PRAME, Survivin and Synovial Sarcoma X for Oncology – Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
CPI-0610 – Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
Dendritic Cell Therapy for Oncology – Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
entinostat – Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
Ferritarg – Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
ficlatuzumab – Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
Iomab-B – Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
ixazomib citrate – Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
JNJ-40346527 – Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
LMP-400 – Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
LMP-776 – Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
MDX-1401 – Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
MK-2206 – Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
Monoclonal Antibodies to Inhibit PD-1/PD-L1 for Hematological Malignancies – Drug Profile 104
Product Description 104
Mechanism of Action 104
R&D Progress 104
Monoclonal Antibody Conjugate to Target CD45 for Oncology – Drug Profile 105
Product Description 105
Mechanism of Action 105
R&D Progress 105
NiCord – Drug Profile 106
Product Description 106
Mechanism of Action 106
R&D Progress 106
nivolumab (recombinant) – Drug Profile 107
Product Description 107
Mechanism of Action 107
R&D Progress 107
NSC-678515 – Drug Profile 112
Product Description 112
Mechanism of Action 112
R&D Progress 112
panobinostat – Drug Profile 113
Product Description 113
Mechanism of Action 113
R&D Progress 113
pembrolizumab – Drug Profile 119
Product Description 119
Mechanism of Action 119
R&D Progress 119
pevonedistat hydrochloride – Drug Profile 123
Product Description 123
Mechanism of Action 123
R&D Progress 123
procarbazine hydrochloride – Drug Profile 125
Product Description 125
Mechanism of Action 125
R&D Progress 125
radretumab – Drug Profile 126
Product Description 126
Mechanism of Action 126
R&D Progress 126
resminostat – Drug Profile 128
Product Description 128
Mechanism of Action 128
R&D Progress 128
ricolinostat – Drug Profile 132
Product Description 132
Mechanism of Action 132
R&D Progress 132
RP-5264 – Drug Profile 134
Product Description 134
Mechanism of Action 134
R&D Progress 134
ruxolitinib phosphate – Drug Profile 136
Product Description 136
Mechanism of Action 136
R&D Progress 136
SD-101 – Drug Profile 141
Product Description 141
Mechanism of Action 141
R&D Progress 141
SL-101 – Drug Profile 143
Product Description 143
Mechanism of Action 143
R&D Progress 143
SL-501 – Drug Profile 144
Product Description 144
Mechanism of Action 144
R&D Progress 144
StemEx – Drug Profile 145
Product Description 145
Mechanism of Action 145
R&D Progress 145
TKM-PLK1 – Drug Profile 146
Product Description 146
Mechanism of Action 146
R&D Progress 146
vinorelbine tartrate liposomal – Drug Profile 148
Product Description 148
Mechanism of Action 148
R&D Progress 148
Hodgkin Lymphoma – Recent Pipeline Updates 150
Hodgkin Lymphoma – Dormant Projects 223
Hodgkin Lymphoma – Discontinued Products 226
Hodgkin Lymphoma – Product Development Milestones 227
Featured News & Press Releases 227
Dec 09, 2014: Affimed Presents Final Data for AFM13 Phase 1 Trial at ASH 227
Dec 08, 2014: Seattle Genetics Highlights Multiple ADCETRIS (Brentuximab Vedotin) Data Presentations in Frontline and Salvage Hodgkin Lymphoma at ASH Annual Meeting 227
Dec 06, 2014: Seattle Genetics and Takeda Report Phase 3 AETHERA Clinical Trial Data from ADCETRIS (Brentuximab Vedotin) in Post-Transplant Hodgkin Lymphoma Patients at Risk of Relapse at ASH Annual Meeting 231
Dec 06, 2014: Opdivo (nivolumab) Demonstrates High Overall Response Rate of 87% for Treatment of Relapsed or Refractory Hodgkin Lymphoma 233
Dec 06, 2014: Data Investigating KEYTRUDA (pembrolizumab), Merck’s Anti-PD-1 Therapy, in Patients with Classical Hodgkin Lymphoma Presented at ASH Annual Meeting 235
Nov 07, 2014: Seattle Genetics to Present Clinical Data from Broad ADCETRIS (Brentuximab Vedotin) Development Program and Novel Antibody-Drug Conjugates at ASH 2014 236
Nov 06, 2014: Takeda Announces Abstracts for ADCETRIS (brentuximab vedotin) in Hodgkin Lymphoma, Systemic Anaplastic Large Cell Lymphoma to be Presented at 56th American Society of Hematology Annual Meeting 238
Oct 13, 2014: Takeda’s Adcetri (brentuximab vedotin) is the first ultra-orphan medicine to be accepted by the SMC via the new assessment process 239
Sep 29, 2014: Seattle Genetics and Takeda Announce Positive Data from Phase 3 AETHERA Clinical Trial of ADCETRIS (Brentuximab Vedotin) for Consolidation in Post-Transplant Hodgkin Lymphoma 240
Sep 26, 2014: Seattle Genetics to Host Conference Call and Webcast on September 29, 2014 Regarding Top-line Data from ADCETRIS (brentuximab vedotin) Phase 3 AETHERA Clinical Trial 242
Appendix 243
Methodology 243
Coverage 243
Secondary Research 243
Primary Research 243
Expert Panel Validation 243
Contact Us 244
Disclaimer 244